Chronic Pain Therapeutics
1. Cymbalta patent expiration
Treatment: Management of fibromyalgia (fm); Method of treating anxiety
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US6596756 (Pediatric) | LILLY | Treatment of fibromyalgia |
Mar, 2020
(5 years ago) | |
| US5508276 | LILLY | Duloxetine enteric pellets |
Jul, 2014
(11 years ago) | |
| US6596756 | LILLY | Treatment of fibromyalgia |
Sep, 2019
(6 years ago) | |
| US5023269 | LILLY | 3-aryloxy-3-substituted propanamines |
Jun, 2013
(12 years ago) | |
|
US5023269 (Pediatric) | LILLY | 3-aryloxy-3-substituted propanamines |
Dec, 2013
(12 years ago) | |
|
US5508276 (Pediatric) | LILLY | Duloxetine enteric pellets |
Jan, 2015
(10 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication(I-617) | Nov 19, 2012 |
| New Indication(I-632) | Nov 04, 2013 |
| Pediatric Exclusivity(PED) | Apr 18, 2016 |
| M(M-61) | Oct 18, 2015 |
| New Patient Population(NPP) | Apr 20, 2023 |
Drugs and Companies using DULOXETINE HYDROCHLORIDE ingredient
Market Authorisation Date: 03 August, 2004
Dosage: CAPSULE, DELAYED REL PELLETS
How can I launch a generic of CYMBALTA before it's drug patent expiration?
More Information on Dosage
CYMBALTA family patents
2. Prialt patent expiration
Treatment: Treatment of pain; Analgesia; Treatment of severe chronic pain via intrathecal infusion of ziconotide in patients also receiving morphine
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5795864 | TERSERA | Stable omega conopetide formulations |
Jun, 2015
(10 years ago) | |
| US5364842 | TERSERA | Method of producing analgesia |
Dec, 2016
(9 years ago) | |
| US8653033 | TERSERA | Method for administering omega-conopeptide |
Oct, 2024
(1 year, 3 months ago) | |
| US9707270 | TERSERA | Method for administering ω-conopeptide |
Oct, 2024
(1 year, 3 months ago) | |
| US8765680 | TERSERA | Method for administering omega-conopeptide |
Oct, 2024
(1 year, 3 months ago) | |
Drugs and Companies using ZICONOTIDE ACETATE ingredient
Market Authorisation Date: 28 December, 2004
Dosage: INJECTABLE
More Information on Dosage
PRIALT family patents